Download Files:

Chol-CTPP

Products Details

Product Description

– Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP). Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function[1].

Web ID

– HY-144825

Shipping

– Room temperature

Applications

– Cancer-Kinase/protease

Molecular Formula

– C144H263N3O53

References

– [1]Jiaqi Lu, et al. Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma. Eur J Med Chem. 2022 Feb 15;230:114093.

Molecular Weight

– 2884.62

SMILES

– O=C(C1=CC=C(C=C1)O)NCCOCCNC(C(CCCC2)=C2C(NCCCCCC(OCCO[C@@H](CC3)CC4=CC[C@]([C@@]5([H])[C@](CC6)([C@@](CC5)([H])[C@H](C)CCCC(C)C)C)([H])[C@@]6([H])[C@]43C)=O)=O)=O.[3].[44]

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– 10 mM in DMSO

Target

– Apoptosis;Reactive Oxygen Species

Pathway

– Apoptosis;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.